Opaleye Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Opaleye Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-50,000	Closed	-$1.96M	–	52
2017 Q1	$1.96M	Buy	+50,000	New	+$1.59M	0.98%	31
2016 Q4	–	Sell	-35,000	Closed	-$795K	–	51
2016 Q3	$795K	Buy	+35,000	New	+$822K	0.42%	40

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Opaleye Management's PTLA Position: Q2 2017 in Review

Opaleye Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 50,000 shares — an estimated $1.96M sold.

Opaleye Management first reported a position in PTLA in Q3 2016 and held it in 2 quarters. The position peaked at $1.96M in Q1 2017. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

Opaleye Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Opaleye Management sold 50,000 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.96M.
Opaleye Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
Opaleye Management's Portola Pharmaceuticals, Inc. position peaked at $1.96M in Q1 2017.
206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.